GenMark Diagnostics, Inc (NASDAQ:GNMK) COO Scott Mendel Sells 1,967 Shares of Stock

GenMark Diagnostics, Inc (NASDAQ:GNMK) COO Scott Mendel sold 1,967 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $6.25, for a total transaction of $12,293.75. Following the completion of the sale, the chief operating officer now directly owns 342,255 shares of the company’s stock, valued at $2,139,093.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Scott Mendel also recently made the following trade(s):

  • On Thursday, May 30th, Scott Mendel sold 2,304 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.60, for a total transaction of $15,206.40.
  • On Friday, May 24th, Scott Mendel sold 1,371 shares of GenMark Diagnostics stock. The shares were sold at an average price of $6.62, for a total transaction of $9,076.02.

NASDAQ GNMK traded up $0.03 on Thursday, hitting $6.31. 1,852 shares of the company were exchanged, compared to its average volume of 357,277. The company’s 50 day moving average price is $6.37 and its 200-day moving average price is $6.82. The company has a debt-to-equity ratio of 3.69, a current ratio of 3.39 and a quick ratio of 2.83. The firm has a market capitalization of $366.46 million, a P/E ratio of -6.96 and a beta of 1.27. GenMark Diagnostics, Inc has a twelve month low of $3.58 and a twelve month high of $8.81.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Monday, August 5th. The medical equipment provider reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.02). The company had revenue of $18.37 million for the quarter, compared to analyst estimates of $17.92 million. GenMark Diagnostics had a negative return on equity of 167.54% and a negative net margin of 63.86%. As a group, equities analysts expect that GenMark Diagnostics, Inc will post -0.8 EPS for the current year.

GNMK has been the topic of several recent analyst reports. Zacks Investment Research downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, June 13th. Canaccord Genuity restated a “buy” rating and set a $10.00 price objective on shares of GenMark Diagnostics in a report on Monday, July 1st. Finally, BidaskClub downgraded GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. GenMark Diagnostics has an average rating of “Hold” and an average price target of $9.67.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC increased its holdings in shares of GenMark Diagnostics by 0.9% in the 1st quarter. FMR LLC now owns 8,470,863 shares of the medical equipment provider’s stock valued at $60,058,000 after purchasing an additional 77,571 shares during the period. Cadian Capital Management LP increased its holdings in shares of GenMark Diagnostics by 9.5% in the 2nd quarter. Cadian Capital Management LP now owns 5,640,748 shares of the medical equipment provider’s stock valued at $36,608,000 after purchasing an additional 488,739 shares during the period. BlackRock Inc. increased its holdings in shares of GenMark Diagnostics by 5.3% in the 2nd quarter. BlackRock Inc. now owns 3,809,177 shares of the medical equipment provider’s stock valued at $24,722,000 after purchasing an additional 193,216 shares during the period. HighTower Advisors LLC increased its holdings in shares of GenMark Diagnostics by 2.8% in the 2nd quarter. HighTower Advisors LLC now owns 2,611,855 shares of the medical equipment provider’s stock valued at $16,950,000 after purchasing an additional 71,814 shares during the period. Finally, Morgan Stanley increased its holdings in shares of GenMark Diagnostics by 434.0% in the 2nd quarter. Morgan Stanley now owns 1,824,449 shares of the medical equipment provider’s stock valued at $11,841,000 after purchasing an additional 1,482,787 shares during the period. Hedge funds and other institutional investors own 89.91% of the company’s stock.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Featured Story: Why do companies pay special dividends?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.